PetMeds Plunges to $34M Loss on Goodwill Impairment, Sales Slide

Ticker: PETS · Form: 10-Q · Filed: 2025-12-19T00:00:00.000Z

Sentiment: bearish

Topics: PetMed Express, PETS, 10-Q, Goodwill Impairment, Net Loss, Sales Decline, Pet Pharmacy

TL;DR

**PETS is bleeding cash and its past acquisitions are worthless; dump it before it gets worse.**

AI Summary

PETMED EXPRESS INC (PETS) reported a significant net loss of $34.152 million for the three months ended June 30, 2025, a stark contrast to the net income of $3.754 million in the prior-year period. This substantial loss was primarily driven by a $27.258 million impairment charge on goodwill and intangible assets. Net sales declined by 22.7% to $51.180 million from $66.207 million in the same quarter last year. Gross profit also decreased to $14.403 million from $19.037 million. The company's operating expenses surged to $48.535 million, largely due to the impairment, compared to $14.651 million previously. Cash and cash equivalents decreased from $54.720 million at March 31, 2025, to $41.127 million at June 30, 2025, with net cash used in operating activities totaling $12.271 million. The company also restated its Q1 2024 financials, reclassifying certain vendor reimbursements from revenue to a reduction in cost of sales, impacting net sales by $1.745 million and cost of sales by $2.811 million.

Why It Matters

This filing reveals a deeply concerning quarter for PetMed Express, marked by a substantial net loss and declining sales, which could significantly erode investor confidence. The $27.258 million goodwill impairment charge indicates that the company's previous acquisitions, likely PetCareRx, are not performing as expected, signaling potential strategic missteps and competitive pressures in the online pet pharmacy market. For employees, this financial downturn could lead to job insecurity or reduced growth opportunities. Customers might see changes in service or product offerings as the company attempts to stabilize. The broader market will watch if this signals a tougher environment for direct-to-consumer pet health, especially with increased competition from larger retailers and veterinary clinics.

Risk Assessment

Risk Level: high — The company reported a net loss of $34.152 million, a significant drop from a $3.754 million net income in the prior year, primarily due to a $27.258 million goodwill impairment charge. Net sales decreased by 22.7% from $66.207 million to $51.180 million, and cash and cash equivalents fell by $13.593 million to $41.127 million, indicating severe operational and financial distress.

Analyst Insight

Investors should consider divesting PETS shares given the substantial net loss, declining sales, and significant goodwill impairment. The company's inability to generate positive cash flow from operations and the restatement of prior financials suggest underlying systemic issues that may persist.

Financial Highlights

revenue
$51.180M
total Assets
$109.839M
net Income
($34.152M)
eps
-$1.65
gross Margin
28.1%
cash Position
$41.127M
revenue Growth
-22.7%

Key Numbers

Key Players & Entities

FAQ

Why did PetMed Express report a net loss in Q1 2025?

PetMed Express reported a net loss of $34.152 million for the three months ended June 30, 2025, primarily due to a $27.258 million impairment charge on goodwill and intangible assets. This charge resulted from a downward revision to the company's forecast and a sustained decrease in its market capitalization.

How did PetMed Express's net sales change in Q1 2025?

PetMed Express's net sales decreased by 22.7% to $51.180 million for the three months ended June 30, 2025, compared to $66.207 million in the same period of 2024. This decline contributed to the overall negative financial performance.

What was the impact of the restatement on PetMed Express's Q1 2024 financials?

The restatement for the quarter ended June 30, 2024, resulted in a $1.745 million reduction in net sales and a $2.811 million reduction in cost of sales. This was due to reclassifying certain vendor promotional sales reimbursements from revenue to a reduction in cost of sales, and reclassifying specific vendor marketing arrangements.

What caused the goodwill impairment for PetMed Express?

The goodwill impairment for PetMed Express was triggered by a downward revision to the company's forecast due to continued revenue declines and a sustained decrease in its stock price and market capitalization during the first quarter of fiscal 2026. This led to a $26.7 million impairment charge.

How much cash did PetMed Express have at the end of Q1 2025?

As of June 30, 2025, PetMed Express had $41.127 million in cash and cash equivalents. This represents a decrease of $13.593 million from the $54.720 million reported at the beginning of the period on March 31, 2025.

What are the primary business activities of PetMed Express?

PetMed Express, operating as PetMeds and PetCareRx, is a nationwide direct-to-consumer pet pharmacy and online provider. They offer prescription and non-prescription medications, food, supplements, supplies, and vet services for dogs, cats, and horses, primarily through their websites, customer contact center, and mobile application.

What is the significance of the 'Accelerated Filer' designation for PetMed Express?

Being an 'Accelerated Filer' means PetMed Express has a public float between $75 million and $700 million and must file its annual reports within 75 days after fiscal year-end and quarterly reports within 40 days after quarter-end. This designation implies a certain level of market capitalization and reporting requirements.

What is the company's fiscal year end?

PetMed Express's fiscal year end is March 31. References to fiscal 2026 or fiscal 2025 in the filing refer to the company's fiscal years ending March 31, 2026, and March 31, 2025, respectively.

How did operating expenses change for PetMed Express in Q1 2025?

Total operating expenses for PetMed Express surged to $48.535 million for the three months ended June 30, 2025, a significant increase from $14.651 million in the prior-year period. This increase was predominantly driven by the $27.258 million impairment of goodwill and intangible assets.

What should investors consider regarding PetMed Express's future outlook?

Investors should note the company's forward-looking statements involve risks and uncertainties, and actual results may differ materially. The significant Q1 2025 net loss, declining sales, and goodwill impairment suggest a challenging outlook, and investors should monitor future filings for signs of stabilization or further deterioration.

Risk Factors

Industry Context

The online pet pharmacy sector is characterized by increasing competition from both specialized online retailers and traditional brick-and-mortar stores expanding their e-commerce presence. Trends include a growing demand for convenience, subscription services, and a wider selection of pet health products. However, regulatory scrutiny and the need for efficient supply chain management are critical for success.

Regulatory Implications

The company's financial restatement for Q1 2024 could attract scrutiny from regulatory bodies like the SEC, potentially leading to further inquiries or compliance requirements. Ensuring accurate and transparent financial reporting is crucial to maintain investor confidence and avoid penalties.

What Investors Should Do

  1. Monitor the company's cash burn rate closely, given the $12.271 million net cash used in operating activities in Q1 2025 and the declining cash position.
  2. Analyze the sustainability of the business model in light of the significant net loss and the $27.258 million goodwill impairment, which suggests a reassessment of asset values.
  3. Evaluate the reasons behind the 22.7% decline in net sales and assess management's strategies to reverse this trend in a competitive market.
  4. Understand the full impact of the Q1 2024 financial restatement on historical performance trends and future comparability.
  5. Assess the company's ability to manage operating expenses, particularly the substantial increase in general and administrative costs, excluding the one-time impairment.

Key Dates

Glossary

Goodwill and intangible assets impairment
A charge taken when the carrying value of goodwill or other intangible assets on the balance sheet is deemed to be higher than their fair value, indicating a loss in value. (A significant $27.258 million impairment charge in Q1 2025 was the primary driver of the company's net loss.)
Net sales
The total revenue generated from the sale of goods or services, net of returns, allowances, and discounts. (Net sales decreased by 22.7% to $51.180 million in Q1 2025 compared to the prior year, indicating a significant drop in business activity.)
Cost of sales
The direct costs attributable to the production or purchase of the goods sold by a company. (Cost of sales decreased to $36.777 million in Q1 2025 from $47.170 million in Q1 2024, reflecting the lower sales volume.)
Gross profit
The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. (Gross profit declined to $14.403 million in Q1 2025 from $19.037 million in Q1 2024, a consequence of lower net sales.)
Operating expenses
The expenses a business incurs in its normal course of operations, excluding costs of goods sold and interest expenses. (Total operating expenses surged to $48.535 million in Q1 2025, largely due to the $27.258 million impairment charge, compared to $14.651 million in Q1 2024.)
Net cash used in operating activities
The amount of cash a company has spent on its core business operations over a period, which can be a negative figure indicating cash outflow. (The company used $12.271 million in operating activities in Q1 2025, an increase from $8.517 million in Q1 2024, indicating a worsening cash burn from operations.)
Restatement
The process of correcting errors or making changes to previously issued financial statements. (PETS restated its Q1 2024 financials, impacting comparability and raising questions about accounting accuracy.)

Year-Over-Year Comparison

Compared to the prior year's Q1, PETMED EXPRESS INC. (PETS) has experienced a dramatic downturn. Net sales have fallen by 22.7% to $51.180 million, and the company has swung from a net income of $3.754 million to a significant net loss of $34.152 million. This reversal is largely attributable to a $27.258 million impairment charge on goodwill and intangible assets, coupled with a substantial increase in operating expenses. The company's cash position has also weakened, with cash and cash equivalents decreasing from $54.720 million to $41.127 million, while net cash used in operating activities increased.

Filing Stats: 4,495 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2025-12-19 16:39:21

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, our results of operations, financial position and our business outlook, business trends and other information, may be forward-looking statements. You can identify these forward-looking statements by the words "believes," "intends," "expects," "might," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "potential," "predicts," "estimates," "anticipates," "future," "goal," and variations of such words or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, estimates and projections will result or be achieved, and actual future results may differ materially from what is expressed in or indicated by the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A, under the heading "Risk Factors," in our Annual Report on Form 10-K for the year ended March 31, 2025 fil

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS. 2 PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share amounts) June 30, 2025 March 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 41,127 $ 54,720 Accounts receivable, less allowance for credit losses of $ 223 and $ 91 , respectively 1,605 2,317 Inventories, net 18,361 16,205 Prepaid expenses and other current assets 6,500 5,330 Prepaid income taxes 299 299 Total current assets 67,892 78,871 Noncurrent assets: Property and equipment, net 28,836 28,859 Intangible and other assets, net 12,257 13,346 Goodwill — 26,658 Operating lease right-of-use assets 854 966 Total noncurrent assets 41,947 69,829 Total assets $ 109,839 $ 148,700 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 20,041 $ 23,564 Sales tax payable 24,994 24,867 Accrued expenses and other current liabilities 10,900 11,711 Current operating lease liabilities 469 461 Deferred revenue 1,108 2,085 Income taxes payable 104 80 Total current liabilities 57,616 62,768 Deferred tax liabilities, net 263 263 Operating lease liabilities, net of current lease liabilities 414 535 Total liabilities 58,293 63,566 Commitments and contingencies (Note 9) Shareholders' equity: Preferred stock, $ 0.001 par value, 5,000,000 shares authorized: Convertible Preferred stock, $ 0.001 par value, with a liquidation preference of $ 4 per share, 250,000 shares authorized ; 2,500 and 2,500 convertible shares issued and outstanding, respectively 9 9 Series A Junior Participating Preferred Stock, $ 0.001 par value, 100,000 shares authorized; no shares issued or outstanding — — Common stock, $ .001 par value, 40,000,000 shares authorized; 20,835,210 and 20,656,822 shares issued and outstanding, respectively 21 21 Additional paid-in capital 19,123 18,560 Retained earnings 32,393 66,544 Total shareholders' equity 51,546 85,134 Tota

View on Read The Filing